Polyrizon Ltd. has announced the successful completion of a major manufacturing upscaling milestone for its proprietary nasal-spray product platform, based on its Capture & Contain (C&C) technology. The company, in collaboration with its CDMO partner, successfully transitioned from small-batch laboratory production to a larger-scale manufacturing run, validating the ability to produce its PL-14 intranasal protective spray at higher volumes while maintaining quality standards. PL-14 is designed to create a fast-acting, moisturizing barrier in the nasal cavity to trap and neutralize airborne allergens. The upscaled manufacturing process will support the production of clinical trial material, with clinical trials expected to begin in 2026. The results of this milestone were announced and have not yet been presented in a scientific forum.